Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer

Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer

Blocking the mitogen‐activated protein kinase (MAPK) pathway with the MEK1/2 inhibitor trametinib has produced promising results in patients with head and neck squamous cell carcinoma (HNSCC). In the current study, we showed that trametinib treatment leads to overexpression and activation of the epi...

Full description

Bibliographic Details
Main Authors: Ofra Novoplansky, Avital B. Shnerb, Divyasree Marripati, Sankar Jagadeeshan, Raghda Abu Shareb, Cristina Conde‐López, Jonathan Zorea, Manu Prasad, Talal Ben Lulu, Ksenia M. Yegodayev, Chen Benafsha, Yushi Li, Dexin Kong, Fengshen Kuo, Luc G. T. Morris, Ina Kurth, Jochen Hess, Moshe Elkabets
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:Molecular Oncology
Subjects:
drug resistance
head and neck cancer
PI3K and EGFR signaling
Trametinib
Online Access:https://doi.org/10.1002/1878-0261.13500

Internet

https://doi.org/10.1002/1878-0261.13500

Similar Items